Matthew R. Henn, Somerville, MA (US); David N. Cook, Brookline, MA (US); Toshiro K. Ohsumi, Cambridge, MA (US); Mary-Jane Lombardo McKenzie, Arlington, MA (US); Kevin D. Litcofsky, Boston, MA (US); Han Zhang, Oakton, VA (US); John Grant Aunins, Doylestown, PA (US); and David Arthur Berry, Brookline, MA (US)
Assigned to Seres Therapeutics, Inc, Cambridge, MA (US)
Filed by Seres Therapeutics, Inc., Cambridge, MA (US)
Filed on Jan. 4, 2021, as Appl. No. 17/140,385.
Application 17/140,385 is a division of application No. 15/990,539, filed on May 25, 2018, granted, now 10,881,696.
Application 15/990,539 is a division of application No. 14/777,252, granted, now 10,076,546, issued on Sep. 18, 2018, previously published as PCT/US2014/030817, filed on Mar. 17, 2014.
Claims priority of provisional application 61/798,666, filed on Mar. 15, 2013.
Prior Publication US 2021/0252079 A1, Aug. 19, 2021
1. A composition comprising a plurality of isolated bacteria and a capsule which encapsulates the plurality of isolated bacteria, wherein the plurality of isolated bacteria comprises a first bacterial operational taxonomic unit (OTU) comprising a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 774, a second bacterial OTU comprising a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 856, a third bacterial OTU comprising a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 880, and a fourth bacterial OTU comprising a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 1670.